Therapy Directory

Palbociclib clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Palbociclib as a study intervention. Browse Palbociclib recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Jul 31, 2026, 1:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

Shown on this page

Local indexed summaries

Local recruiting

The trial list below is retrieved from the live ClinicalTrials.gov search API for Palbociclib. Results on this page are currently sorted by Recently updated.

Showing 1–12 of 77 matching trials for Palbociclib.

Indexed local directory records.

Top conditions

Breast Cancer 21 Metastatic Breast Cancer 8 Advanced Malignant Solid Neoplasm 6 Recurrent Malignant Solid Neoplasm 4 Advanced Breast Cancer 3 Advanced Solid Tumors 3

Top sponsors

National Cancer Institute (NCI) 7 AstraZeneca 6 Hoffmann-La Roche 6 Pfizer 6 Alliance Foundation Trials, LLC. 3 M.D. Anderson Cancer Center 3

Top locations

Boston, Massachusetts 37 New York, New York 34 Nashville, Tennessee 32 Houston, Texas 29 Philadelphia, Pennsylvania 27 St Louis, Missouri 22

Indexed official records

Open in full search

Conditions: HR+/HER2- Breast Cancer
Interventions: Abemaciclib, BGB-43395, Letrozole, Palbociclib, Ribociclib; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 1,056 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2037
U.S. locations: 25
States / cities: Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 22 more

Conditions: Sarcoma
Interventions: Palbociclib, Pembrolizumab; Drug
Lead sponsor: John Rieth; Other
Eligibility: 12 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: HPV-unrelated Head and Neck Squamous Cell Carcinoma
Interventions: Cetuximab, Palbociclib; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 5
States / cities: Worthington, Minnesota • Kansas City, Missouri • St Louis, Missouri + 2 more

Conditions: Breast Cancer
Interventions: Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Letrozole, Arm D: Ribociclib + Letrozole; Drug
Lead sponsor: Celcuity Inc; Industry
Eligibility: 18 Years and older
Enrollment: 1,180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 22
States / cities: Duarte, California • Fullerton, California • Los Angeles, California + 19 more

Conditions: Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
Interventions: Alpelisib, Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Echocardiography Test, Fluorouracil, Fulvestrant, Ipatasertib, Leucovorin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Mutation Carrier Screening, Neratinib Maleate, Nilotinib Hydrochloride Monohydrate, Olaparib, Oxaliplatin, Paclitaxel, Palbociclib, Panitumumab, Positron Emission Tomography, Selumetinib Sulfate, Sotorasib; Drug · Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 2,900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 475
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 352 more

Conditions: Carcinoma, Renal Cell, Von Hippel-Lindau Disease
Interventions: Belzutifan, Cabozantinib, Everolimus, Lenvatinib, Nivolumab, Palbociclib; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Advanced Breast Cancer
Interventions: Abemaciclib, Anastrozole, Camizestrant, Exemestane, Fulvestrant, Letrozole, Palbociclib, Ribociclib, Saruparib (AZD5305); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 52
States / cities: Gilbert, Arizona • Fountain Valley, California • Glendale, California + 45 more

Conditions: Advanced Solid Tumors, Lymphoma, Non-Hodgkin, Multiple Myeloma
Interventions: Abemaciclib, Atezolizumab and Talazoparib, Dabrafenib plus Trametinib, Fam-Trastuzumab Deruxtecan-Nxki (TDxD), Futibatinib, Nivolumab and Ipilimumab, Olaparib, Palbociclib, Regorafenib, Sunitinib, Talazoparib, Temsirolimus, Trastuzumab and Pertuzumab, Tucatinib plus Trastuzumab Subcutaneous (SC), Vemurafenib and Cobimetinib; Drug
Lead sponsor: American Society of Clinical Oncology; Other
Eligibility: 12 Years and older
Enrollment: 4,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 174
States / cities: Birmingham, Alabama • Phoenix, Arizona • Auburn, California + 137 more

Conditions: Breast Neoplasms, Neoplasm Metastasis
Interventions: Abemaciclib, Anastrozole, Exemestane, Fulvestrant, LY4064809, Letrozole, Palbociclib, Placebo, Ribociclib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 920 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 116
States / cities: Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 101 more

Conditions: Metastatic Breast Cancer
Interventions: Palbociclib, Palbociclib 125mg, Ribociclib, Ribociclib 600mg; Drug
Lead sponsor: American Society of Clinical Oncology; Other
Eligibility: 65 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 67
States / cities: Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 54 more

Conditions: Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Neratinib Maleate, Palbociclib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 186
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 149 more

Conditions: ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)
Interventions: AZD8421, Abemaciclib, Camizestrant, Palbociclib, Ribociclib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: St Louis, Missouri • Providence, Rhode Island • Nashville, Tennessee + 1 more

About this Palbociclib clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Palbociclib as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Palbociclib.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Palbociclib clinical trials

Filter and sort this therapy

Top conditions

Top sponsors

Top locations

Indexed official records

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

Palbociclib and Pembrolizumab in Sarcoma

Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

About this Palbociclib clinical trials directory page